Buprenorphine Microdose Induction for the Management of Prescription Opioid Dependence: A Case Series in Primary Care

By

Jonathan L. Robbins, MD, MS (1), Honora Englander MD (2), Jessica Gregg MD, PhD (3)

1. Assistant Professor, Division of General Internal Medicine & Geriatrics, Section of Addiction Medicine, Oregon Health & Science University, Portland, OR
2. Associate Professor, Division of Hospital Medicine, Section of Addiction Medicine, Oregon Health & Science University, Portland, OR
3. Associate Professor, Division of General Internal Medicine & Geriatrics, Section of Addiction Medicine, Oregon Health & Science University, Portland, OR

Correspondence to:
Jonathan Robbins, MD, MS
Division of General Internal Medicine & Geriatrics
Mail Code: L-475
School of Medicine
Oregon Health & Science University
3181 SW Sam Jackson Park Rd.
Portland, OR. 97239

Telephone: 503-494-6514
E-mail: robbijon@ohsu.edu

Word Count: 1411 (excluding references)

Conflicts of Interest: None to report

Funding: None to report

Keywords: buprenorphine microinduction, pain, opioid dependence, opioid tapering

© Copyright 2020 by the American Board of Family Medicine.
Ahead-of-print; non-copy edited version.
Abstract:

Prescription opioid dependence remains a major source of morbidity and mortality in the US. Patients previously on high dose opioids may poorly tolerate opioid tapers. Current guidelines support the use of buprenorphine therapy in opioid tapering protocols, even among patients without a diagnosis of opioid use disorder. Buprenorphine microinduction protocols can be used to transition patients to buprenorphine therapy without opioid withdrawal. From November 2019 – April 2020 we transitioned 8 patients on high dose prescribed opioids for pain to sublingual buprenorphine-naloxone using a microdose protocol without any evidence of precipitated withdrawal. Six of these patients remain on buprenorphine-naloxone and report improved analgesia. Due to its simplicity, the buprenorphine microinduction protocol can be easily adapted for telemedicine and may help to prevent unnecessary clinic visits and opioid-related admissions in the setting of social distancing regulations during the Coronavirus 2019 pandemic.
Background:

Prescription opioid dependence remains a significant source of morbidity and mortality, with nearly 15,000 deaths attributable to prescription opioid overdose in 2018.\textsuperscript{1-3} Shared-decision making regarding the risks and benefits of chronic opioid therapy and voluntary opioid tapering can help to mitigate opioid side effects.\textsuperscript{4,5} However, rapid or forced opioid tapering can destabilize patients and lead to opioid withdrawal and a loss of function, and some patients struggle with slow tapers\textsuperscript{6,7}

In the \textit{CDC Guideline for Prescribing Opioids for Chronic Pain}, Dowell et al. advocate for sublingual (SL) buprenorphine products for patients on prescription opioids who develop an opioid use disorder (OUD), but the authors did not explicitly recommend SL buprenorphine as an alternative to tapering in patients with opioid dependence.\textsuperscript{8} Opioid dependence is the physiologic adaptation to chronic opioid use through the development of tolerance and withdrawal;\textsuperscript{6} OUD is characterized by craving, use despite consequences, loss of control, and compulsive use and is diagnosed using the \textit{Diagnostic and Statistical Manual of Mental Disorders, 5th Edition} (DSM-5).\textsuperscript{9} In 2019 Drs. Lembke, Chou, and Ballantyne argued for widespread use of SL buprenorphine as a complement to opioid tapering and to treat prescription opioid dependence, even in the absence of an OUD.\textsuperscript{10} Their rationale was that SL buprenorphine has important safety advantages, particularly in minimizing unintentional overdose and improved quality of life.\textsuperscript{10} This recommendation was further codified in the 2019 U.S. Health and Human Services guidelines on opioid tapering and discontinuation.\textsuperscript{11}
Buprenorphine is a partial agonist at the µ opioid receptor with high binding affinity and slow dissociation from the receptor. Low-dose transdermal and buccal buprenorphine products are FDA-approved for chronic pain and are typically used in opioid naïve patients, while higher-dose SL buprenorphine is FDA-approved for OUD only and considered off-label for opioid dependence or pain. The partial agonist effect has significant safety benefits when compared to full agonist opioids; buprenorphine products are unlikely to cause respiratory arrest unless combined with other central nervous system depressants. Furthermore, buprenorphine has been hypothesized to reverse opioid hyperalgesia, a common and frustrating complication of long-term opioid therapy.

Because buprenorphine has a higher binding affinity for the µ receptor than full agonist opioids, immediately starting buprenorphine in a patient taking full agonist will abruptly displace the full agonist from the µ receptor, leading to precipitated withdrawal. To avoid precipitated withdrawal, during conventional buprenorphine inductions patients abstain from full agonist opioids until they experience moderate to severe opioid withdrawal. The conventional buprenorphine induction process is a barrier to treatment for both patients and providers. This is particularly true in patients with chronic pain, who fear both withdrawal and an increase in pain.

Buprenorphine microdose inductions were first described by Hämmig in 2016 (the Bernese protocol) and involve repetitive, low dose exposure to buprenorphine over several days, such that partial and full opioid agonists can be continued concurrently without precipitated withdrawal.
Buprenorphine microinduction can improve care of patients with OUD by minimizing opioid withdrawal symptoms, reducing the dropout rate during induction, and decreasing fear of withdrawal. Microinductions have been shown to be safe and effective in inpatient and outpatient settings for patients with OUD. Microinductions for opioid dependent patients on long-term opioid therapy (LTOT) for chronic, non-cancer pain. Here we describe our experience using microdose buprenorphine inductions for patients with prescription opioid dependence in an urban, academic general internal medicine practice.

Case Series:
From November 2019 – April 2020 providers completed 8 microdose buprenorphine inductions in opioid dependent patients on LTOT using a modified Bernese protocol. (Table 1) We adapted a more gradual approach than the Bernese protocol, and taper rather than abruptly stop full agonist opioids, to improve patient acceptance of SL buprenorphine therapy. (Table 2) Our protocol served as a general guide for the microinduction process, with minor variations in SL buprenorphine dosing and speed of full agonist taper depending on clinical circumstances. We used the SL buprenorphine-naloxone combination product unless otherwise stated.

The average patient age was 63 years, all were white, and half were women. The insurance break-down was 1 privately insured, 2 on Medicaid, 3 Medicare-Medicaid, and 2 Medicare only. The average morphine equivalent daily dose (MEDD) at the time of microinduction was 127 mg, although many patients had previously tapered from higher full agonist doses. Physical and
mental comorbidities were common (Table 1). Two of the 8 patients met the DSM-5 criteria for mild OUD at the time of microinduction; the remaining 6 had opioid dependence without an OUD.

All 8 patients tolerated SL buprenorphine microinduction without precipitated withdrawal. Two patients were unable to remain on buprenorphine-naloxone due to side effects that persisted after the induction phase and after tapering full agonist opioids. These included oversedation for one patient and persistent nausea for another. The side effects did not abate despite dose reduction or a trial of SL buprenorphine monoprodut. The 6 patients that successfully transitioned to SL buprenorphine reported stable to improved pain.

Discussion:

Our institution has adopted a general dose limit for LTOT of 90 MEDD for non-cancer pain. Many patients are unable to taper to this dose due to profound disruption of the endogenous opioid system caused by years of exogenous high dose opioids. For these patients with opioid dependence, transition to SL buprenorphine therapy is increasingly supported by federal guidelines and considered best practice. Patients and providers in our primary care practice have readily adopted the practice of SL buprenorphine microinductions. The microinduction protocol has eliminated concerns for precipitating opioid withdrawal during standard induction, which is a well-documented barrier to the use of buprenorphine.
In our practice patients on LTOT are often older with significant medical and psychiatric comorbidities, and can be resistant to medication changes. Unlike other SL buprenorphine microinduction protocols for patients on LTOT, we choose to taper full agonist opioids by no faster than 25% a week after buprenorphine is initiated, rather than abruptly stopping opioids. At a dose of 16 mg of SL buprenorphine, 90% of the µ receptors are occupied, and it is unlikely that discontinuing full agonist opioids after microinduction would lead to significant opioid withdrawal. Our approach recognizes the emotional distress and emotional pain that can accompany changes to opioid homeostasis, a concept referred to as hyperkatifeia. We found that engaging in shared-decision making about the speed of the full agonist opioid taper after initiating SL buprenorphine has increased acceptance of therapy and makes this transition more tolerable.

In the setting of the Coronavirus 2019 (COVID-19) pandemic, our practice minimized in-person visits and shifted clinical care to telephone or video visits, and some staff and providers have been redeployed to respiratory clinics. Conventional SL buprenorphine inductions can involve significant time commitments from providers and ancillary staff, including the active management of opioid withdrawal and daily titration of SL buprenorphine after home or office induction. Buprenorphine microinduction is well-suited for telemedicine; in-person follow-up needs are minimal and can be addressed via phone or video visits. Opioid overdoses have increased during COVID-19, and there is an increasing call for low barrier SL tele-buprenorphine which has been facilitated by temporary changes in regulatory standards which allow initiation of SL buprenorphine telephonically without an initial in-person visit.
There are still several barriers to buprenorphine microinduction in our practice. Community pharmacists may not be familiar with microinduction protocols, and have refused to fill SL buprenorphine prescriptions for patients on full agonist opioids. Even after an explanatory phone call from our providers, this has undermined patient trust in the microinduction process. Practically, cutting SL 2 mg buprenorphine tablets into quarters can be imprecise and inaccurate, although this has not interrupted the efficacy of the microinduction. Buprenorphine manufacturers could consider creating SL tablets and films at lower doses to accommodate the increasing number of opioid dependent patients who will be transitioning to SL buprenorphine.

**Conclusions:**

Microdose buprenorphine inductions have been well-tolerated in opioid dependent patients in a general internal medicine outpatient practice. Our case series adds to a growing body of evidence that SL buprenorphine microinduction is safe and feasible in diverse practice settings and populations. Despite the absence of randomized or case-controlled trials, we believe that microdose buprenorphine inductions should be offered to patients on LTOT who meet clinical criteria for a transition to SL buprenorphine therapy. This technique is low risk and can greatly reduce unnecessary suffering in the form of opioid withdrawal. Importantly, the FDA indication for high-dose SL buprenorphine products should expand to opioid dependence to reflect current guidelines. Buprenorphine microinductions are well suited for telemedicine and virtual care, which has important applications during the COVID-19 pandemic.
References:


<table>
<thead>
<tr>
<th>Patient</th>
<th>Age</th>
<th>Gender</th>
<th>Full Agonist Opioid at Time of Induction</th>
<th>MEDD (mg)</th>
<th>Substance Use Disorder (by DSM-V)</th>
<th>Psychological/Medical comorbidity</th>
<th>Pain Generators</th>
<th>Maintenance SL buprenorphine dosage at 30 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>53</td>
<td>Female</td>
<td>Fentanyl 100 mcg</td>
<td>240</td>
<td>None</td>
<td>Rheumatoid arthritis, paroxysmal atrial fibrillation, major depressive disorder</td>
<td>Rheumatoid arthritis</td>
<td>4 mg – 8 mg – 8 mg</td>
</tr>
<tr>
<td>2</td>
<td>67</td>
<td>Male</td>
<td>Hydrocodone/acetaminophen 10 – 325 mg 8 per day</td>
<td>80</td>
<td>None</td>
<td>None</td>
<td>Shoulder, knee, cervical, lumbar osteoarthritis</td>
<td>Not applicable; Unable to tolerate buprenorphine 2 mg due to oversedation; back on full agonist at previous dose</td>
</tr>
<tr>
<td>3</td>
<td>69</td>
<td>Male</td>
<td>Oxycodone 30 mg 5 times per day</td>
<td>225</td>
<td>Benzodiazepine use disorder, mild</td>
<td>Major depressive disorder, hypogonadism, paroxysmal atrial fibrillation</td>
<td>Failed back surgery syndrome</td>
<td>8 mg three times daily and continues on oxycodone 15 mg three times daily on slow taper</td>
</tr>
<tr>
<td>4</td>
<td>62</td>
<td>Female</td>
<td>Oxycodone 10 mg five times per day</td>
<td>75</td>
<td>Alcohol use disorder, moderate</td>
<td>Bipolar 2 disorder</td>
<td>Chronic pancreatitis, chronic abdominal pain</td>
<td>Not applicable; Unable to tolerate buprenorphine due to nausea, switched back to full agonist, slowly tapering</td>
</tr>
<tr>
<td>5</td>
<td>63</td>
<td>Female</td>
<td>Methadone 10 mg twice daily; hydromorphone 2 mg four times daily</td>
<td>92</td>
<td>Opioid use disorder, mild</td>
<td>Major depressive disorder, adrenal insufficiency, benzodiazepine dependence</td>
<td>Fibromyalgia, knee osteoarthritis</td>
<td>4 mg four times daily</td>
</tr>
<tr>
<td>6</td>
<td>67</td>
<td>Male</td>
<td>Hydromorphone 4 mg 5 times daily; morphine extended release 15 mg daily</td>
<td>95</td>
<td>Opioid use disorder, mild</td>
<td>Parkinson’s disease, severe odynophagia</td>
<td>Multiple orthopedic surgeries, Parkinson’s disease</td>
<td>8 mg three times daily</td>
</tr>
<tr>
<td>7</td>
<td>70</td>
<td>Female</td>
<td>Morphine extended release 30 mg twice daily; morphine immediate release 15 mg three times daily</td>
<td>105</td>
<td>None</td>
<td>Major depressive disorder</td>
<td>Neuropathy, fibromyalgia, knee osteoarthritis</td>
<td>8 mg three times daily</td>
</tr>
<tr>
<td>8</td>
<td>53</td>
<td>Male</td>
<td>Oxycodone 10 mg 7 times daily</td>
<td>105</td>
<td>None</td>
<td>Ischemic heart failure, uncontrolled type 2 diabetes mellitus</td>
<td>Chronic leg wounds, lumbar spine osteoarthritis</td>
<td>8 mg twice daily</td>
</tr>
</tbody>
</table>
Table 2: Outpatient micro-induction protocol using SL 2 mg buprenorphine/naloxone tablets or films

<table>
<thead>
<tr>
<th>Day</th>
<th>Bup/nlx dose and frequency</th>
<th>Full agonist opioid</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.5 mg daily (1/4 tablet or film)</td>
<td>No change</td>
</tr>
<tr>
<td>2</td>
<td>0.5 mg BID</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>1 mg BID (1/2 tablet or film)</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>2 mg BID</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>2 mg TID</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>4 mg TID</td>
<td></td>
</tr>
<tr>
<td>7 and beyond</td>
<td>Per provider discretion</td>
<td>Taper by 25% weekly</td>
</tr>
</tbody>
</table>